 |
 |
|
|
| |
Novelty and chemical diversity
Graffinity´s proprietary low molecular weight compound
libraries on its chemical
microarrays are based on small molecule fragments. The design principles
of these
collections allow insight into relevant structural features
early in the discovery
process and provide the basis for rapid optimization procedures.
Lead structures for your
targets
Graffinity uses its integrated discovery platform with unique
fragment-based libraries, in combination with its proprietary SPR
imaging technology to take proteins from target to novel initial
leads. Graffinity´s low affinity screening technology generates
novel molecular ideas which are unattainable with competing
technologies.
Target prioritisation
approach for discovery on a genomic scale
Graffinity can provide chemical annotation of any number of
proteins. Working with many proteins in parallel per project
the screening data can be used to prioritize targets for further
development in drug discovery and/or provide the basis of a
lead development program. Due to the array technology this approach
is very rapid and cost effective.
|
|
|
|
|
|
| |
 |
|
The Graffinity process delivers:
• Window to novel, diverse chemistry
• Fragments and low affinity binders
built
the basis for novelty
• Novel binding modes can be
characterized
early
• Fastest read on drug-ability of
targets
• Earliest look at SAR that is
technically
possible
• Scalable technology and process to
any
number of targets |
|
|
|
|
|
|
